This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
Biosimilars have driven down the costs of originator biologics, but it isn't clear whether those savings are being passed on to patients or increasing access to the drugs.
In a new data analysis, Harvard researchers find that insulin manufacturers have filed multiple patents on delivery devices following the original insulin product approval.
In a systematic review, outcomes such as remission and loss of response were similar between patients with IBD who continued their original biologic and those who switched to a biosimilar.